Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as expression of TGF-β-regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β may benefit these patients. METHODS: Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment, were analyzed for expression of the TGF-β-regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS). RESULTS: In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313 at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups. Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β-regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced THBS1 expression and improved MRSS after fresolimumab treatment. CONCLUSION: The rapid inhibition of TGF-β-regulated gene expression in response to fresolimumab strongly implicates TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses markers of skin fibrosis. TRIAL REGISTRATION: Clinicaltrials.gov NCT01284322.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a small open label single center study, Fresolimumab (180), a high affinity TGFβ inactivating monoclonal antibody was recently tested in SSc patients, and reduced TGFβ dependent gene expression in skin biopsies and improved modified Rodnan skin score (180).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Open source clustering software
de Hoon, M. J. L., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,043
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationTransforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Systemic sclerosis: a prototypic multisystem fibrotic disorder
Varga, J., & Abraham, D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31139 · Cited by 1,163
Type beta transforming growth factor: a bifunctional regulator of cellular growth.
Roberts, A. B., Anzano, M. A., Wakefield, L. M., Roche, N. S., Stern, D. F., & Sporn, M. B. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.119 · Cited by 1,094
Research works printed but not linked: 3
- Derynck R, Miyaono K, eds. The TGF-Beta Family. Cold Spring Harbor Monograph Series 50. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 2007.
- 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q · doi:10.1002/1529-0131(200011)43:11<2445::aid-anr11>3.0.co;2-q
- Rice, Arthritis Rheum.
Cited by
Items 201–300 of 350
Miwa, S., Yokota, M., Ueyama, Y., Maeda, K., Ogoshi, Y., Seki, N., Ogawa, N., Nishihata, J., Nomura, A., Adachi, T., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00679 · Cited by 14
Ubiquitination in Scleroderma Fibrosis and Its Treatment
Long, Y., Chen, W., Du, Q., Zuo, X., & Zhu, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02383 · Cited by 15
P311, Friend, or Foe of Tissue Fibrosis?
Stradiot, L., Mannaerts, I., & van Grunsven, L. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01151 · Cited by 21
Treatable Traits in Systemic Sclerosis
Amati, F., Bongiovanni, G., Tonutti, A., Motta, F., Stainer, A., Mangiameli, G., Aliberti, S., Selmi, C. F., & Santis, M. D. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08969-x · Cited by 13
Targeted Therapy in Systemic Sclerosis
Baron, M. G. (2016) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10257 · Cited by 13
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza, A., Álvarez, M., Maria, A. D., Margolin, K. A., Melero, I., & Ascierto, M. L. (2022) · Cells · doi:10.3390/cells11193147 · Cited by 15
Advances in biological and targeted therapies for systemic sclerosis
Mulcaire-Jones, E., Low, A. H. L., Domsic, R. T., Whitfield, M. L., & Khanna, D. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2196009 · Cited by 15
Self-citationSystemic sclerosis: The need for structured care
Morrisroe, K., Frech, T., Gote-Schniering, J., Maurer, B., & Nikpour, M. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.004 · Cited by 14
Recent advances in the treatment of skin involvement in systemic sclerosis
Asano, Y. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0047-4 · Cited by 16
Recent progress in systemic sclerosis-interstitial lung disease
Castelino, F. V., & Dellaripa, P. F. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000544 · Cited by 13
Drugs in phase I and phase II clinical trials for systemic sclerosis
Chung, M. P., & Chung, L. S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1743973 · Cited by 14
Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical Trials
Siani, A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00292-2 · Cited by 14
Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis
Gumkowska-Sroka, O., Kotyla, K., Mojs, E. H., Palka, K., & Kotyla, P. J. (2023) · Pharmaceuticals · doi:10.3390/ph16081066 · Cited by 16
Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials
Roofeh, D., Lescoat, A., & Khanna, D. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1836156 · Cited by 12
Emerging biomarkers in systemic sclerosis
Manetti, M. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000324 · Cited by 12
Altered AP-1, RUNX, and EGR chromatin dynamics drive human fibrotic lung disease
Valenzi, E., Jia, M., Gerges, P., Fan, J., Tabib, T., Behera, R., Mao, H., Xue, D., Ju, E.-M., Zhou, Y., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.12.003 · Cited by 14
Self-citationA Positive Loop Formed by SOX11 and Periostin Upregulates TGF-β Signals Leading to Skin Fibrosis
Nanri, Y., Nunomura, S., Honda, Y., Takedomi, H., Yamaguchi, Y., & Izuhara, K. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.12.008 · Cited by 10
The level of TGF-b in sera of patients with primary Sjögren’s syndrome
Maślińska, M., Paradowska‐Gorycka, A., Mańczak, M., Kostyra-Grabczak, K., & Kwiatkowska, B. (2019) · Reumatologia/Rheumatology · doi:10.5114/reum.2019.91276 · Cited by 10
Toward Molecular Stratification and Precision Medicine in Systemic Sclerosis
Noviani, M., Chellamuthu, V. R., Albani, S., & Low, A. H. L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.911977 · Cited by 10
Pedersen, R. S., Nissen, N. I., Jensen, C., Thorlacius‐Ussing, J., Manon‐Jensen, T., Olesen, M. L., Langholm, L. L., Diab, H. M. H., Jørgensen, L. N., Hansen, C. P., et al. (2022) · Biomolecules · doi:10.3390/biom12091315 · Cited by 10
Liu, W., Nicol, L. E., & ORWOLL, E. S. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01188-2 · Cited by 10
CD22 and CD72 contribute to the development of scleroderma in a murine model
Zhao, C., Matsushita, T., Nguyen, V. T. H., Tennichi, M., Fujimoto, M., Takehara, K., & Hamaguchi, Y. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.12.007 · Cited by 10
Kocic, G. M., Gajić, M., Tomović, K., Hadži-Djokić, J., Anderluh, M., & Šmelcerović, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15618 · Cited by 10
Targeting fibroblasts in pathological bone formation: mechanisms and treatments
Zhang, Q., Song, Q., Li, Z., Wu, X., Chen, Y., & Lin, H. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1612950 · Cited by 12
CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling
Naoi, H., Suzuki, Y., Miyagi, A., Horiguchi, R., Aono, Y., Inoue, Y., Yasui, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300285 · Cited by 12
Pashaei, M., Farhadi, E., Kavosi, H., Madreseh, E., Enayati, S., Mahmoudi, M., & Amirzargar, A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01536-6 · Cited by 9
Emerging drugs and therapeutics for systemic sclerosis
Lee, J. J., & Pope, J. E. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257607 · Cited by 10
Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor‐ß
Chaigne, B., Clary, G., Gall, M. L., Dumoitier, N., Fernandez, C., Lofek, S., Chafey, P., Moinzadeh, P., Krieg, T. M., Denton, C. P., et al. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800069 · Cited by 9
Interstitial lung disease in systemic sclerosis (systemic scleroderma)
Ananyeva, L. P., Tyurin, I. E., KONEVA, O. A., GARZANOVA, L., & Lila, A. M. (2021) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2021-1s-1-62 · Cited by 9
News and failures from recent treatment trials in systemic sclerosis
Denton, C. P., Yee, P., & Ong, V. H. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2020.19187 · Cited by 9
Abdulla, M., & Chew, T. S. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000729 · Cited by 9
Rosenstein, R. K., Rose, J. J., Brooks, S. R., Tsai, W. L., Gadina, M., Pavletic, S. Z., Nagao, K., & Cowen, E. W. (2023) · JID Innovations · doi:10.1016/j.xjidi.2023.100246 · Cited by 8
Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review
Muehlebach, M. E., Pradeep, S., Chen, X., Arnold, L., Arthur, A. E., Gan, G. N., & Thomas, S. M. (2025) · Cells · doi:10.3390/cells14241969 · Cited by 11
Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
Migayron, L., Bordes, S., Closs, B., Sénéschal, J., & Boniface, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1405215 · Cited by 9
Funauchi, M., & Kinoshita, K. (2022) · Clinical Medicine Insights Arthritis and Musculoskeletal Disorders · doi:10.1177/11795441211066307 · Cited by 8
The Mechanistic Implications of Gene Expression Studies in SSc: Insights From Systems Biology
Taroni, J., Mahoney, J. M., & Whitfield, M. L. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0072-0 · Cited by 8
Self-citationSarcoidosis and Systemic Sclerosis: Strange Bedfellows
Yu, M., Sandhu, V. K., Lezcano, S. D., Maken, K., Kirk, S., & Torralba, K. D. (2017) · Case Reports in Rheumatology · doi:10.1155/2017/7851652 · Cited by 8
The immunopathology of systemic sclerosis
van Laar, J. M., & Varga, J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0517-1 · Cited by 8
Is macitentan not a treatment option for digital ulcers in systemic sclerosis?
Asano, Y. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.08.67 · Cited by 8
Leask, A., Fadl, A., & Naik, A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2323528 · Cited by 7
Systemic Sclerosis and the Liver
Green, E. W., Kahl, L. E., & Jou, J. H. (2021) · Clinical Liver Disease · doi:10.1002/cld.1074 · Cited by 7
Didier, K., Robbins, A., Antonicelli, F. D., Pham, B. N., Giusti, D., & Servettaz, A. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.05.016 · Cited by 12
Papa, N. D., & Zaccara, E. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.02.004 · Cited by 9
Antifibrotics in systemic sclerosis
Martín-López, M., & Carreira, P. E. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101671 · Cited by 7
Yamamoto, A., Saito, T., Hosoya, T., Kawahata, K., Asano, Y., Sato, S., Mizoguchi, F., Yasuda, S., & Kohsaka, H. (2021) · Arthritis & Rheumatology · doi:10.1002/art.42042 · Cited by 7
Tam, A. Y. Y., Khan, K., Xu, S., Bergin, M., Huang, L., Arroyo-Colon, E., Cheng, D., Verderio, E. A. M., Ong, V. H., Denton, C. P., et al. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43104 · Cited by 7
Allergic Contact Dermatitis: Immunopathology and Potential Therapeutic Strategies
Funch, A. B., Geisler, C., & Bonefeld, C. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207175 · Cited by 7
Su, H., Fan, X., Nie, C., Tang, X., Hu, J., Xu, K., Zhang, L., & Ma, D. (2026) · Biomolecules · doi:10.3390/biom16010072 · Cited by 6
Gasperin-Bulbarela, J., Castro-Ceseña, A. B., Camacho-Villegas, T. A., Lugo-Fabres, P. H., Diaz-Martinez, N. E., Padilla‐Camberos, E., Echavarría, R., & Licea-Navarro, A. F. (2021) · Applied Sciences · doi:10.3390/app11031164 · Cited by 6
Han, L. W., Jamalian, S., Hsu, J. C., Sheng, X. R., Yang, X., Yang, X., Monemi, S., Hassan, S., Yadav, R., Tuckwell, K., et al. (2024) · Rheumatology and Therapy · doi:10.1007/s40744-024-00670-5 · Cited by 6
The Pathogenesis of Scleroderma
Gupta, L., Ahmed, S., & Zanwar, A. A. (2017) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.219083 · Cited by 8
Kim, L., Rubenstein, R. N., Chu, J. J., Allen, R. J., Mehrara, B. J., & Nelson, J. A. (2022) · Journal of Reconstructive Microsurgery · doi:10.1055/s-0042-1742731 · Cited by 7
The Exciting Future for Scleroderma
Distler, J. H. W., Riemekasten, G., & Denton, C. P. (2023) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2023.01.014 · Cited by 7
Al-Adwi, Y., Atzeni, I. M., der Meer, B. D., Abdulle, A. E., van Roon, A. M., Stel, A. J., van Goor, H., Smit, A. J., Westra, J., & Mulder, D. J. (2023) · Antioxidants · doi:10.3390/antiox12040794 · Cited by 6
Yadav, R., Sukumaran, S., Lutman, J., Mitra, M. S., Halpern, W., Sun, T., Setiadi, A., Neighbors, M., Sheng, X. R., Yip, V., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.07.005 · Cited by 6
Khanna, D., Kramer, F., Höfler, J., Ghadessi, M., Sandner, P., Allanore, Y., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Pope, J. E., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae150 · Cited by 7
Pisciotta, A., Tinco, R. D., Bertani, G., Orlandi, G., Bertoni, L., Pignatti, E., Orciani, M., Sena, P., Bertacchini, J., Salvarani, C., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1196023 · Cited by 7
Pulmonary Hypertension in Scleroderma– Evaluation and Management
Chennakesavulu, P. V., Uppaluri, S., Koyi, J., Jhaveri, S., Avanthika, C., Sakhamuri, L. T., Ashokbhai, P. K., & Singh, P. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101468 · Cited by 7
Immune Imbalance Drives Keloid Pathogenesis: Emerging Targets for Precision Immunotherapy
Chen, Q., Wan, S., Duan, Y., Yan, J., & Zhang, M. (2026) · Advances in Wound Care · doi:10.1177/21621918261417702 · Cited by 6
Erectile dysfunction and Peyronie’s disease: from biologics to nanomedicine-enabled therapies
Kaltsas, A., & Hatzichristou, D. G. (2026) · Sexual Medicine · doi:10.1093/sexmed/qfag019 · Cited by 6
Exploring the Antifibrotic Mechanisms of Ghrelin: Modulating TGF-β Signalling in Organ Fibrosis
Li, M., Zheng, C., Wang, H., & Wang, S. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.38 · Cited by 5
Mitra, M. S., Halpern, W., Lepherd, M., Corpuz, J., Adedeji, A. O., Yadav, R., Duarte, I., Sun, T., Arron, J. R., Turley, S. J., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf059 · Cited by 5
New Approaches in Management of Generalized Scleroderma (Progressive Systemic Sclerosis)
Ananieva, L., & Moscow, R. F. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-7-32-39 · Cited by 4
Diagnosis and treatment of interstitial lung disease in scleroderma systematica
Ananyeva, L. P. (2018) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2018-2-12-21 · Cited by 7
Mlakar, L., Garrett, S. M., Watanabe, T., Sanderson, M., Nishimoto, T., Heywood, J., Helke, K. L., Pilewski, J. M., Herzog, E. L., & Feghali‐Bostwick, C. A. (2022) · Biomedicines · doi:10.3390/biomedicines10112861 · Cited by 6
Sacchetti, C., & Bottini, N. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0655-7 · Cited by 8
Fallet, B., & Walker, U. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1832466 · Cited by 5
Current therapy of interstitial pneumonia associated with systemic scleroderma
Ananieva, L. (2020) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-520-531 · Cited by 6
The role of thrombospondin-1 in dermatological conditions
Chen, L.-S., Zheng, B., Zhao, C.-Y., He, C., & Xing-hua, G. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1724955 · Cited by 4
Bagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 5
Inhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities
Gao, X., Li, X., Zhang, C., Zhou, J., Gu, K., Liu, X., & Bai, C. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157048 · Cited by 4
Parvizi, R., Gong, Z., Jarnagin, H. C., Toledo, D. M., Abel, T. R., Popovich, D., Morrisson, M. J., Wood, T. A., Shenk, S., Sarkar, M. K., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.10.033 · Cited by 4
Self-citationTargeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis
Aung, W. W., Hamaguchi, Y., & Matsushita, T. (2022) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12288 · Cited by 7
Benfaremo, D., Agarbati, S., Mozzicafreddo, M., Paolini, C., Svegliati, S., & Moroncini, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612548 · Cited by 5
Busschers, E., Chen, Y., Adeyeye, M., Song, I.-W., Busse, E., Castellon, A., Ruiz, O., Meyers, N., Bae, Y., Ambrose, C. G., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf068 · Cited by 4
Steiner, C. A., & Higgins, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_23 · Cited by 6
Newer Insights into the Management of Interstitial Lung Disease in Systemic Sclerosis
Mango, R. L., Ryu, J. H., & Makol, A. (2017) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.219084 · Cited by 5
Pathogenesis of Crohn's Disease- and Ulcerative Colitis-Related Strictures
Ko, J. Z.-H., Abraham, J. P., & Shih, D. Q. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811388-2.00003-8 · Cited by 4
Hepatitis C Virus and Inflammation
Kumar, B., Ramachandran, A., & Waris, G. (2018) · InTech eBooks · doi:10.5772/intechopen.75916 · Cited by 4
Editorial: Genomic Advances in Systemic Sclerosis: It Is Time for Precision
Varga, J., & Roberson, E. D. O. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39285 · Cited by 4
Targeting the nasty nestin to shoot lung fibrosis
Burgy, O., Crestani, B., & Bonniaud, P. (2022) · European Respiratory Journal · doi:10.1183/13993003.03146-2021 · Cited by 4
Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis
Han, X., Wang, X., Huang, J., & Yang, J. Y. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152811 · Cited by 3
Langerin+ Dendritic Cells in Cutaneous Fibrosis: The TGF-β1 Signaling Axis
Lv, X., Xiang, C., Zheng, Y., Lv, X.-L., & Zhou, W.-X. (2025) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s549199 · Cited by 5
Nanomedicine-Driven Modulation of Signaling Pathways in Hepatic Fibrosis
Ji, P., Li, Y., Jin, Y., Dong, Y., Li, L., Ma, Z., Liu, L., Zhang, Y., & Ren, Z. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s418132 · Cited by 5
TGF-β signaling pathway in the regulations of development and disease
Sun, H., Wei, S., & Xi, Q. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0326 · Cited by 5
Fibrosis mechanisms in systemic sclerosis and new potential therapies
Barile, R., Rotondo, C., Rella, V., Trotta, A., Cantatore, F. P., & Corrado, A. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae169 · Cited by 3
Tsuchida, Y., & Fujio, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814307-0.00015-3 · Cited by 5
Ramzan, A., Yousaf, M. A., Rashid, M. U., Basheera, S., & Malkani, N. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2268198 · Cited by 3
Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders
Aribi, M. (2017) · InTech eBooks · doi:10.5772/63032 · Cited by 3
Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars
Shi, Y., & Li, L. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020148 · Cited by 2
Recent updates on engineered nanomedicines for treatment of fibrosis
Ziada, A. R., Xin, C., & Elzoghby, A. O. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2628236 · Cited by 2
Transforming Growth Factor Beta (TGF-β) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC)
Kudinov, A. E., & Beck, T. N. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_4 · Cited by 3
Ten years after: rheumatology research from bench to bedside
Bottini, N., & Firestein, G. S. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.126 · Cited by 2
Investigational drugs for the treatment of scleroderma: what’s new?
Colic, J., Campochiaro, C., Hughes, M., Matucci‐Cerinic, M., & Dagna, L. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2242762 · Cited by 2
Potjewijd, J., Tobal, R., Damoiseaux, J. G. M. C., & van Paassen, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2675635 · Cited by 2
Yang, L., Li, L., Mao, J., & Liang, Q. (2026) · British Journal of Dermatology · doi:10.1093/bjd/ljag258 · Cited by 1
Tyagi, R., & Kant, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638345 · Cited by 2
Wu, M., Yang, Q., Xie, Y., Hou, Y., & Xue, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1649570 · Cited by 1
Homey, B. (2015) · Der Hautarzt · doi:10.1007/s00105-015-3684-z · Cited by 1
Biomarkers in Scleroderma: Current Status
Gupta, L., Phatak, S. B., & Edavalath, S. (2017) · Indian Journal of Rheumatology · doi:10.4103/0973-3698.219087 · Cited by 1
Metadata
- Authors
- Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., Spiera, R. F., Christmann, R. B., Gordon, J. K., Weinberg, J., Simms, R. W., & Lafyatis, R.
- Affiliations
- Boston University (US)
- Hospital for Special Surgery (US)
- Dartmouth College (US)
- Corresponding author
- Lafyatis, Robert
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-06-22
- Volume
- 125
- Issue
- 7
- Pages
- 2795-2807
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4563675
- OpenAlex
- W2155049325
- Cited by
- 351
- References
- 53
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 30 · 2023: 27 · 2022: 37 · 2021: 30 · 2020: 28 · 2019: 24 · 2018: 42 · 2017: 41 · 2016: 34 · 2015: 13
- FWCI
- 34.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Scleroderma Research Foundation
- Bristol-Myers Squibb
- GlaxoSmithKline
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- United Therapeutics Corporation
- Dr. Ralph and Marian Falk Medical Research Trust
- Hospital for Special Surgery
- Cytori Therapeutics
- National Institutes of Health
- Genentech
- Clinical and Translational Science Institute, Boston University
- National Cancer Institute (P30CA023108)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR051089, R03AR062721, P30AR061271, P50AR060780)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Keywords
- systemic sclerosis, diffuse cutaneous systemic sclerosis, TGF-beta inhibition, skin fibrosis, thrombospondin-1, cartilage oligomeric matrix protein, myofibroblasts, connective tissue growth factor, SERPINE1, modified Rodnan skin score, pharmacodynamic biomarkers, neutralizing antibodies
- MeSH terms
- Adult, Antibodies, Monoclonal, Female, Genetic Markers, Humans, Male, Middle Aged, Scleroderma, Systemic, Gene Expression, Transforming Growth Factor beta, Treatment Outcome, Thrombospondin 1, Myofibroblasts, Antibodies, Monoclonal, Humanized, Cartilage Oligomeric Matrix Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.